AdaptHealth Q2: $144M Goodwill Impairment Drives Net Loss, FY2026 EBITDA Guidance Slashed by ~$200M
AHCO is trading near its 52-week low of $8.505 (1.1% above the low).
Summary
AdaptHealth posted a $145.3M Q2 net loss after a $144.2M goodwill impairment and cut FY2026 Adjusted EBITDA guidance by ~$200M, citing cost pressures and the Diabetes Health divestiture. The stock trades near its 52-week low.
Key Events · Earnings and Guidance · AHCO
-
Q2 Net Loss Driven by Goodwill Impairment
Net loss attributable to AdaptHealth was $145.3M, compared to net income of $4.2M a year ago, primarily due to a $144.2M pre-tax non-cash goodwill impairment in the Respiratory Health and Wellness at Home segments.
-
FY2026 Adjusted EBITDA Guidance Slashed
Full-year Adjusted EBITDA guidance was cut to $490M-$520M from $680M-$730M, reflecting a $100M impact from the Diabetes Health divestiture, $55M from the West Coast capitated contract, $30M from a manufacturer price increase, and $15M from other portfolio actions.
-
Organic Revenue Growth of 15.9%
Q2 net revenue rose 12.7% to $740.3M, with organic growth of 15.9% across all segments, driven by record volume gains and the ramp of a large capitated agreement.
-
Portfolio Restructuring Continues
Subsequent to quarter-end, the company entered a definitive agreement to sell its Diabetes Health business for $235M cash and formed a joint venture combining its eCommerce asset with a leading sleep retailer, adding home sleep testing capabilities.
Analysis · AHCO · Industrial Applications And Services
AdaptHealth reported a sharp Q2 net loss driven by a $144.2 million non-cash goodwill impairment, signaling that the fair values of its Respiratory Health and Wellness at Home units have fallen below their carrying values. While organic revenue grew 15.9%, Adjusted EBITDA declined 3.2% and the company slashed full-year Adjusted EBITDA guidance by roughly $200 million at the midpoint, citing margin pressure from a capitated contract ramp, a manufacturer price increase, and the removal of the Diabetes Health business from continuing operations. The stock is trading near its 52-week low, and the combination of a large impairment, lowered outlook, and negative free cash flow raises concerns about the pace of the portfolio restructuring and the underlying profitability of the remaining businesses.
At the time of this filing, AHCO was trading at $8.60 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $8.51 to $13.43. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.